IL1B and DEFB1 polymorphisms increase susceptibility to invasive mold infection after solid-organ transplantation

Journal of Infectious Diseases

Volumn 211, Issue 10, 2015, Pages 1646-1657

  Wójtowicz, Agnieszka ^a   Gresnigt, Mark S ^p   Lecompte, Thanh ^f,g   Bibert, Stephanie ^a   Manuel, Oriol ^a,b   Joosten, Leo A B ^p   Rüeger, Sina ^c,e   Berger, Christoph ^h   Boggian, Katia ^j   Cusini, Alexia ^k   Garzoni, Christian ^k,l   Hirsch, Hans H ^m   Weisser, Maja ⁿ   Mueller, Nicolas J ⁱ   Meylan, Pascal R ^a,d   Steiger, Jürg ^o   Kutalik, Zoltan ^a,e   Pascual, Manuel ^b   Van Delden, Christian ^f,g   Van De Veerdonk, Frank L ^p   Bochud, Pierre Yves ^a   more..

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Transplantation Center   (Switzerland)

^c Institute of Tropical and Preventive Medicine   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^f Service of Transplantation   (Switzerland)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^k UNIVERSITY OF BERN   (Switzerland)

^l Department of Internal Medicine ^*  (Switzerland)

^m Clinica Luganese   (Switzerland)

ⁿ Division of Infectious Diseases and Hospital Epidemiology   (Switzerland)

^o UNIVERSITY HOSPITAL BASEL   (Switzerland)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Aspergillosis; Genetic susceptibility; Innate immunity; Interleukin 1 beta; Invasive mold infections; Single nucleotide polymorphism; Solid organ transplant

Indexed keywords

BETA DEFENSIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; BETA DEFENSIN; DEFB1 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN;

ADULT; ALTERNARIA; ARTICLE; ASPERGILLUS; BETA DEFENSIN 1 GENE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; FUNGAL COLONIZATION; FUSARIUM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; INTERLEUKIN 1BETA GENE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SWITZERLAND; SYSTEMIC MYCOSIS; ZYGOMYCETES; ADVERSE EFFECTS; AGED; FUNGUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GRAFT RECIPIENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MYCOSES;

ADULT; AGED; BETA-DEFENSINS; COHORT STUDIES; FEMALE; FUNGI; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; MYCOSES; ORGAN TRANSPLANTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSPLANT RECIPIENTS;

EID: 84929660541     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu636     Document Type: Article

References (46)

1. Mahillo B, Carmona M, Alvarez M, White S, Noel L, Matesanz R. 2009 global data in organ donation and transplantation: Activities, laws, and organization. Transplantation 2011; 92:1069-74.
2. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601-14.
3. Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study. Clin Infect Dis 2005; 41:52-9.
4. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43(suppl 1):S49-58.
5. Singh N, Husain S, AST Infectious Diseases Community of Practice. Aspergillosis in solid organ transplantation. Am J Transplant 2013; 13(suppl 4):228-41.
6. Lamoth F, Rubino I, Bochud PY. Immunogenetics of invasive aspergillosis. Med Mycol 2011; 49(suppl 1):S125-36.
7. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011; 11:275-88.
8. KollerMT, van Delden C,MullerNJ, et al.Design and methodology of the Swiss Transplant Cohort Study (STCS): A comprehensive prospective nationwide long-term follow-up cohort. Eur J Epidemiol 2013; 28:347-55.
9. Lecompte T, Garzoni C, Mueller N, et al. Fungal infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. Present at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 9-12 September 2012.
10. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
11. Husain S, Mooney ML, Danziger-Isakov L, et al. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant 2011; 30:361-74.
12. Manuel O, Kralidis G, Mueller NJ, et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2013; 13:2402-10.
13. Gresnigt MS, Becker KL, Smeekens SP, et al. Aspergillus fumigatus-Induced IL-22 Is Not Restricted to a Specific Th Cell Subset and Is Dependent on Complement Receptor 3. J Immunol 2013; 190:5629-39.
14. Therneau T. A Package for Survival Analysis in S. R package version 2.37-7, 2014.
15. Lass-Florl C, Roilides E, Loffler J, Wilflingseder D, Romani L. Minireview: host defence in invasive aspergillosis. Mycoses 2013; 56:403-13.
16. Mircescu MM, Lipuma L, van Rooijen N, Pamer EG, Hohl TM. Essential role for neutrophils but not alveolar macrophages at early time points following Aspergillus fumigatus infection. J Infect Dis 2009; 200:647-56.
17. Gresnigt MS, Netea MG, van de Veerdonk FL. Pattern recognition receptors and their role in invasive aspergillosis. Ann N Y Acad Sci 2012; 1273:60-7.
18. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360:2426-37.
19. Gresnigt MS, Bozza S, Becker KL, et al. A polysaccharide virulence factor from Aspergillus fumigatus elicits anti-inflammatory effects through induction of Interleukin-1 receptor antagonist. PLoS Pathog 2014; 10: e1003936.
20. Dinarello CA. Overview of the interleukin-1 family of ligands and receptors. Semin Immunol 2013; 25:389-93.
21. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002; 13:323-40.
22. Sainz J, Perez E, Gomez-Lopera S, Jurado M. IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate C-reactive protein level. J Clin Immunol 2008; 28:473-85.
23. Brouwer MC, Read RC, van de Beek D. Host genetics and outcome in meningococcal disease: A systematic review and meta-analysis. Lancet Infect Dis 2010; 10:262-74.
24. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70:616-23.
25. Liu Y, Li S, Zhang G, et al. Genetic variants in IL1A and IL1B contribute to the susceptibility to 2009 pandemic H1N1 influenza A virus. BMC Immunol 2013; 14:37.
26. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398-402.
27. Wen AQ, Gu W, Wang J, et al. Clinical relevance of IL-1beta promoter polymorphisms (-1470,-511, and-31) in patients with major trauma. Shock 2010; 33:576-82.
28. Chourasia D, Achyut BR, Tripathi S, Mittal B, Mittal RD, Ghoshal UC. Genotypic and functional roles of IL-1B and IL-1RN on the risk of gastroesophageal reflux disease: the presence of IL-1B-511 T/IL-1RN 1 (T1) haplotype may protect against the disease. Am J Gastroenterol 2009; 104:2704-13.
29. Hall SK, Perregaux DG, Gabel CA, et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta genewith secretion of interleukin-1 beta protein. Arthritis Rheum 2004; 50:1976-83.
30. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008; 83:181-94.
31. Read RC, Cannings C, Naylor SC, et al. Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 2003; 138:534-41.
32. Sudenga SL, Wiener HW, Shendre A, Wilson CM, Tang J, Shrestha S. Variants in interleukin family of cytokines genes influence clearance of high risk HPV in HIV-1 coinfected African-American adolescents. Hum Immunol 2013; 74:1696-700.
33. Vamvakopoulos J, Green C, Metcalfe S. Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol 2002; 32:2988-96.
34. Linzmeier R, Ho CH, Hoang BV, Ganz T. A 450-kb contig of defensin genes on human chromosome 8p23. Gene 1999; 233:205-11.
35. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009; 30:131-41.
36. Yang D, Chertov O, Bykovskaia SN, et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999; 286:525-8.
37. Schroeder BO, Wu Z, Nuding S, et al. Reduction of disulphide bonds unmasks potent antimicrobial activity of human beta-defensin 1. Nature 2011; 469:419-23.
38. Jurevic RJ, Bai M, Chadwick RB, White TC, Dale BA. Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: high-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls. J Clin Microbiol 2003; 41:90-6.
39. Prado-Montes de Oca E, Velarde-Felix JS, Rios-Tostado JJ, Picos-Cardenas VJ, Figuera LE. SNP 668C (-44) alters a NF-kappaB1 putative binding site in non-coding strand of human beta-defensin 1 (DEFB1) and is associated with lepromatous leprosy. Infect Genet Evol 2009; 9:617-25.
40. Naslavsky MS, Rocha CR, Lima Filho JL, Crovella S. Predicting alternative candidates as binding sites to DEFB1 668 (-44) SNP: A long way from statistical association with multifactorial diseases. Infect Genet Evol 2009; 9:1129-31.
41. Nurjadi D, Herrmann E, Hinderberger I, Zanger P. Impaired betadefensin expression in human skin links DEFB1 promoter polymorphisms with persistent Staphylococcus aureus nasal carriage. J Infect Dis 2013; 207:666-74.
42. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004; 21:241-54.
43. Kanda N,Watanabe S. Increased serum human beta-defensin-2 levels in atopic dermatitis: relationship to IL-22 and oncostatin M. Immunobiology 2012; 217:436-45.
44. Madan T, Kaur S, Saxena S, et al. Role of collectins in innate immunity against aspergillosis. Med Mycol 2005; 43(suppl 1):S155-63.
45. Vaid M, Kaur S, Sambatakou H, Madan T, Denning DW, Sarma PU. Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Clin Chem Lab Med 2007; 45:183-6.
46. Saxena S, Madan T, Shah A, Muralidhar K, Sarma PU. Association of polymorphisms in the collagen region of SP-A2 with increased levels of total IgE antibodies and eosinophilia in patients with allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2003; 111: 1001-7.